William Brenham Hooper
Research Data SpecialistCards
About
Research
Publications
2026
Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes.
Bhagchandani SH, Ehrenzeller S, Pires IS, Chaudhary N, Booth CJ, Kwon DI, Koutsioumpa C, Baker CA, Laxton C, Santos Guedes de Sá K, Matthews C, Gill P, Li S, Olszowka A, Hudak A, Fischer S, Bayarri-Olmos R, Hooper WB, Iwasaki A. Bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) for mucosal vaccination against genital herpes. Sci Immunol 2026, 11: eaea6419. PMID: 42319912, DOI: 10.1126/sciimmunol.aea6419.Peer-Reviewed Original ResearchThis study investigates a novel vaccine strategy using BEACONs, a mucosal adjuvant, to enhance localized immunity and protect against genital herpes by boosting tissue-resident T cells and antibodies.Systematic multi-reference vertebrate ACE2 sequence similarity analysis predicts species susceptibility to SARS-related sarbecoviruses
Frank J, Gan E, Hooper W, Ott I, Iwasaki A. Systematic multi-reference vertebrate ACE2 sequence similarity analysis predicts species susceptibility to SARS-related sarbecoviruses. Scientific Reports 2026, 16: 13995. PMID: 41851226, PMCID: PMC13133125, DOI: 10.1038/s41598-026-41410-9.Peer-Reviewed Original ResearchAngiotensin-converting enzyme 2Host rangeCross-species virus transmissionSequence similarity analysisSusceptible speciesReceptor sequencesEven-toed ungulatesReceptor angiotensin-converting enzyme 2Potential host rangeSARS-CoV-2 glycoproteinReceptor sequence similaritySequence similarityACE2 sequenceSequence informationComputational pipelineSARS-CoV-2 variantsHost sequencesSARS-CoV-2Resistant speciesResistance to infectionSpeciesSARS-CoVReporter virusInfection of humansSequence
2025
Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial
Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Christian D, Coppi A, Warner F, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Mouslmani M, Hooper W, Putrino D, Carr K, Charnas L, De Jesus M, Nepert D, Abreu P, Ziegler F, Spertus J, Iwasaki A, Krumholz H. Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial. The Lancet Infectious Diseases 2025, 25: 936-946. PMID: 40188838, DOI: 10.1016/s1473-3099(25)00073-8.Peer-Reviewed Original ResearchPhysical health summary scoreBaseline to dayAdverse eventsNirmatrelvir-ritonavirSARS-CoV-2 infectionDouble-blindStudy drug-related treatment-emergent adverse eventsDrug-related treatment-emergent adverse eventsTreatment-emergent adverse eventsIntention-to-treat populationWeek 6Baseline to week 6Documented SARS-CoV-2 infectionActive liver diseaseEffective pharmacological interventionsLong COVIDAcute medical illnessSafety populationPatient-Reported Outcomes Measurement Information SystemEarly treatment terminationRenal impairmentTreat long-COVIDPlacebo-ControlledEfficacy endpointRandomised controlled trials